Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14288831 | 0.96 | POLB (0.58) | POLBALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL11860611 | 0.82 | KMT2A (0.45) | POLBALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL11866150 | 0.81 | ALDH1A1 (0.42) | POLBALDH1A1KDM4EMAPTGAA | |
| SCHEMBL11856807 | 0.81 | OPRK1 (0.42) | POLBALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL11873109 | 0.81 | GABRG2 (0.51) | POLBALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL11782432 | 0.81 | DDB1 (0.40) | POLBALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL12715433 | 0.79 | SMN1; SMN2 (0.45) | POLBALDH1A1KDM4EMAPTGAA | |
| SCHEMBL14282594 | 0.79 | POLB (0.71) | POLBALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL14265194 | 0.79 | POLB (0.71) | POLBALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL12714525 | 0.78 | TMEM97 (0.43) | POLBALDH1A1KDM4EMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3985732-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-10-12 | — | — | US | claimed |
| US-3968230-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1976-07-06 | — | — | US | claimed |
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-7279573-B2 | Amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279573-B2 | Amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| EP-0861250-B1 | AMIDINE AND ISOTHIOUREA DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| US-6140322-A | Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase | ASTRA AKTIEBOLAG (SE) | 2000-10-31 | — | — | US | disclosed |
| US-3985732-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3985732-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3985732-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3968230-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
| US-3968230-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
| US-3947408-A | ANTIANXIETY AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | GHRHR, NPPA, SSTR5 | POLB 2501/4885ALDH1A1 2890/4885GABRA1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.